Valuation
- Market cap
- 996,023,000
- Revenue TTM
- $2,976,000
- Net income TTM
- $-148,647,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -4,994.86%
- Debt to equity
- 0.00
Trading
- Volume
- 192,500
- Avg volume
- 256,714
- Day's range
- $20.05 – $21.60
- Shares out
- 48,059,000
- Stochastic %K
- 35%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $35.75
Company profile
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammato...
Show more
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 865 9628
- Website
- https://odysseytx.com
- Address
- 51 Sleeper Street, Suite 800, Boston, United States
Latest news
No headlines yet.
